Innovative 3D-printed vaginal ring for progesterone delivery to support IVF pregnancies
Official title: CRP - Innovative 3D Printed Intravaginal Ring AnelleO-PRO, the first Single Administration of Progesterone for Infertility
Funded at Anelleo, INC. · NIH-11409203 · Data updated 2026-11-12
A new 3D-printed vaginal ring delivers progesterone over 28 days for IVF patients, aiming to improve pregnancy success with fewer rings and less frequent dosing.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Anelleo, INC. NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | September 20, 2026 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $499,604 |
| NIH project number | 1SB1HD120142-01A1 |
| Project ID | NIH-11409203 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals undergoing IVF who require sustained progesterone support during the first 8-10 weeks of pregnancy.
✕Less likely to help
Patients not undergoing IVF or not requiring progesterone supplementation may not benefit from this product.
What this research studies
This project develops ANLO102, an intravaginal ring that provides steady progesterone release throughout the IVF treatment period. Using advanced 3D printing (CLIP technology), the ring is designed for rapid, cost-effective fabrication and continuous drug delivery. Patients would insert the ring as directed, potentially reducing daily dosing and improving comfort and adherence during the 8-10 week early pregnancy window. The research builds on prior IVR work to address gaps in sustained progesterone supplementation for ART success.
Why it matters
Potential benefit: If successful, this approach could simplify progesterone support during IVF, improve adherence, and potentially increase pregnancy outcomes.
How similar studies have gone: Previous IVR approaches exist; this project advances a next-generation 3D-printed ring to improve dosing convenience and fabrication efficiency.
Where this research is happening
-
Anelleo, INC.
Chapel Hill, United States Active
Researchers
- Principal investigator: Janusziewicz, Rima — Anelleo, INC.
- Study coordinator: Janusziewicz, Rima
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to endometriosis-related infertility
This grant explores how molecular changes in endometriosis contribute to infertility, with the aim of finding better ways to diagnose and treat the condition.
-
Oral FSH receptor activator drugs to lower infertility treatment costs
A new oral drug approach aims to improve fertility treatments by using a small molecule that activates the FSH receptor, potentially making infertility care more affordable.
-
Prediction of ART outcomes for male factor infertility using single-molecule chromatin stenciling in sperm
A new test called sperm Fiber-seq is being developed to better predict how well ART will work for couples dealing with male-factor infertility.
-
TLR4 blocker for improving fertility in PCOS
A promising, already-approved drug (disulfiram) will be tested to see if it can reduce inflammation and improve ovulation in women with PCOS.
-
Genetics of Male Infertility: Accelerating Discovery and Clinical Impact
This grant aims to uncover the genetic causes of male infertility (azoospermia) to improve diagnosis and pave the way for personalized treatments.
-
Infertility and long-term health in Hispanic women with Mexican heritage
A large study will follow Hispanic women with Mexican heritage to understand how infertility relates to cancer, diabetes, and heart-related illnesses over time.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.